The agreement covers the development, registration, promotion and distribution of Actair(R) in Japan and Taiwan, and of the Japanese cedar pollen tablet in Japan. The clinical development of Actair(R) will be launched in 2011 in order to prepare the license application. For the Japanese cedar pollen tablet, a specific development plan will be initiated through close collaboration between the two partners, since the product is exclusively aimed at the Japanese market.
Stallergenes will receive: - an immediate upfront payment of Euros 24 million, - up to Euros 46 million in development and regulatory milestones payments, - as well as sales milestones.
Furthermore, Stallergenes will be entitled to royalty payments on net sales of the products by Shionogi & Co., Ltd.
Shionogi & Co., Ltd. will be responsible for the clinical development, registration, marketing and sales of the products covered by this agreement in Japan. Stallergenes will be responsible for tablet production and supply, and early-stage development.
"We are enthusiastic about the prospect of collaborating with Stallergenes, the world leader in sublingual allergen immunotherapy, and are very looking forward to bringing new treatment options of sublingual immunotherapy to a huge number of allergic rhinitis patients in Japan, most of whom suffer from allergy to house dust mite and/or Japanese cedar," declared Dr. Isao Teshirogi, President of Shionogi & Co., Ltd.
"We are delighted to team up with Shionogi & Co., Ltd., one of Japan's
biggest pharmaceutical companies, an R&D-based organization and a ke
Copyright©2010 PR Newswire.
All rights reserved